CurrentCapital BluecrossPolicy MP 2.331

Genetic testing for Marfan syndrome, thoracic aortic aneurysms and dissections, and related disorders

Defines medical necessity criteria for individual genetic testing, targeted familial variant testing, and panels (focused vs broad) for Marfan syndrome, Ehlers-Danlos syndrome type IV, thoracic aortic aneurysms/dissections (TAAD), and related disorders for Capital BlueCross lines of business. Also lists relevant CPT codes and describes investigational exclusions for broad panels.

Policy Summary

PayerCapital Bluecross

PolicyGenetic testing for Marfan syndrome, thoracic aortic aneurysms and dissections, and related disorders

Policy CodePolicy MP 2.331

Change TypeMaterial and administrative revisions

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionProviders must document that the individual has signs/symptoms of a connective tissue disorder and that a definitive diagnosis cannot be made using established clinical diagnostic criteria to support medical necessity for individual testing or focused panel testing.

SourceLink

POLICY UPDATE CHANGES

03/05/2025 Minor Review: Removed genes (LOX, SMAD3, TGFB2, MYLK, PRKG1) from medically necessary policy statement.

03/23/2023 Minor Review: Added genes (LOX, SMAD3, TGFB2, MYLK, PRKG1) to policy per AHA/ACC guidelines and added CPT code 81479.

05/16/2022 Minor Review: Added Ehlers-Danlos syndrome Type IV to policy statements; updated coding so 81411 is now medically necessary.

03/21/2024 Consensus Review: Added CPT code 81401.

Effective 06/11/2025 administrative update removing the Benefit Variations Section and updating the Disclaimer.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy addresses genetic testing for Marfan syndrome, Ehlers-Danlos syndrome type IV, thoracic aortic aneurysms/dissections (TAAD), and related disorders. Individual gene testing and panels that are limited to specified focused gene groups (e.g., FBN1 and MYH11; ACTA2, TGFBR1, and TGFBR2; and COL3A1) are considered medically necessary when clinical signs/symptoms are present but a definitive diagnosis cannot be made using established diagnostic criteria. By contrast, genetic testing panels that are broad/multi-gene and not limited to these focused genes are considered investigational. Representative syndromes noted in the policy include Marfan syndrome, vascular Ehlers-Danlos syndrome (EDS type IV), Loeys-Dietz syndrome (LDS), arterial tortuosity syndrome, and familial TAAD.

High-level policy summary

Focused gene groups considered medically necessary3 focused gene groups: (FBN1 & MYH11); (ACTA2, TGFBR1, TGFBR2); (COL3A1)

Broad/multi-gene panels statusConsidered investigational (not medically necessary) when not limited to focused gene groups

Representative syndromes enumeratedIncludes ~6 representative syndromes: Marfan, EDS type IV, Loeys‑Dietz, arterial tortuosity, familial TAAD, others

Medical-Necessity Criteria

Medically necessary - Individual genetic testing and focused panels

Individual genetic testing or panels comprised entirely of focused genetic testing limited to specified genes may be considered medically necessary when:

ALL of the following

Signs and symptoms of a connective tissue disorder are present
A definitive diagnosis cannot be made using established clinical diagnostic criteria
ALL of the following
- ONE OF
  - FBN1 and MYH11

Investigational / Not Medically Necessary

Investigational / Not medically necessary

Genetic testing panels that are not limited to focused genetic testing are considered investigational because evidence is insufficient:

Panels that are not limited to focused testing (i.e., broad/multi-gene panels beyond the specified focused gene groups)

Considered investigational

Rationale: broad multi-gene panels that are not limited to the specified focused genes are considered investigational because there is insufficient evidence to demonstrate their analytic validity, clinical validity, and clinical utility compared with focused testing.

Coding

Covered when medically necessary (molecular/genetic procedure CPT codes)CPTCovered

81401
81405
81408
81410
81411
81479

Related encounter / family history ICD-10 codes listedICD-10

Z13.79	Encounter for screening for genetic and chromosomal anomalies.
Z82.79	Family history of other congenital malformations, deformations, and chromosomal abnormalities

Note: identification of a CPT code in this policy does not guarantee coverage or payment; payment is subject to the member's benefit terms, contract limitations, and eligibility on the date of service, and services must be medically necessary and appropriate.

Provider Actions & Documentation Requirements

Documentation Required

Document clinical signs/symptoms and inability to make diagnosis clinically

Providers must document that the individual has signs/symptoms of a connective tissue disorder and that a definitive diagnosis cannot be made using established clinical diagnostic criteria to support medical necessity for individual testing or focused panel testing.

Documentation Required

Document known familial pathogenic variant for targeted familial testing

For targeted familial variant testing in an asymptomatic individual, providers must document the presence of a known pathogenic variant in the family.

Background, Evidence, and Definitions

Genetic testing can confirm a diagnosis when clinical criteria are insufficient, guide clinical management and surveillance (including decisions about aortic repair), and enable presymptomatic testing of at-risk family members. The policy supports use of targeted individual testing or focused gene panels when clinical findings suggest a specific syndrome, but states that broad multi-gene panels that are not limited to focused genes are considered investigational due to limited evidence on their overall benefits and validity.

Key evidence metrics

FBN1 detection rate in probands meeting Ghent criteria90%–97%

EDS type IV sequencing detection rate>95%

Fraction of thoracic aortic aneurysms that are genetically related≈5%

Familial variant: Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives.

Revision History

06/11/2025Administrative/ClarifiedLatest

Effective 06/11/2025 administrative update removing the Benefit Variations Section and updating the Disclaimer.

03/05/2025Material

03/05/2025 Minor Review: Removed genes (LOX, SMAD3, TGFB2, MYLK, PRKG1) from medically necessary policy statement.

03/21/2024Administrative/Clarified